Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass

American Journal of Obstetrics and Gynecology

Volumn 203, Issue 3, 2010, Pages 228.e1-228.e6

  Moore, Richard G ^a   Jabre Raughley, Moune ^a   Brown, Amy K ^b   Robison, Katina M ^a   Miller, M Craig ^c   Allard, W Jeffery ^c   Kurman, Robert J ^d   Bast, Robert C ^e   Skates, Steven J ^f  

^a BROWN UNIVERSITY   (United States)

^b HARTFORD HOSPITAL   (United States)

^c Medivice Consulting   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

CA125; HE4; ovarian cancer; pelvic mass; ROMA

Indexed keywords

CA 125 ANTIGEN; HE 4 ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE MARKER; EPITHELIAL OVARY CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; MENOPAUSE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; OVARY CYST; PELVIS; PELVIS SURGERY; PELVIS TUMOR; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE; SURGICAL TECHNIQUE; TUMOR LOCALIZATION; ULTRASOUND;

EID: 77956342398     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2010.03.043     Document Type: Article

References (21)

1. J.P. Curtin Management of the adnexal mass Gynecol Oncol 55 1994 S42 S46
2. National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up Gynecol Oncol 55 1994 S4 S14
3. American Cancer Society Cancer facts & figures 2009 168
4. W.J. Hoskins, W.P. McGuire, and M.F. Brady The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma Am J Obstet Gynecol 170 1994 974 979
5. J.P. Curtin, R. Malik, E.S. Venkatraman, R.R. Barakat, and W.J. Hoskins Stage IV ovarian cancer: impact of surgical debulking Gynecol Oncol 64 1997 9 12
6. R.E. Bristow, F.J. Montz, L.D. Lagasse, R.S. Leuchter, and B.Y. Karlan Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer Gynecol Oncol 72 1999 278 287
7. R.C. Young, D.G. Decker, and J.T. Wharton Staging laparotomy in early ovarian cancer JAMA 250 1983 3072 3076
8. T. Paulsen, K. Kjaerheim, J. Kaern, S. Tretli, and C. Trope Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals Int J Gynecol Cancer 16 Suppl 2006 11 17
9. M.J. Engelen, H.E. Kos, and P.H. Willemse Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma Cancer 106 2006 589 598
10. C.C. Earle, D. Schrag, and B.A. Neville Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients J Natl Cancer Inst 98 2006 172 180
11. K.C. Giede, K. Kieser, J. Dodge, and B. Rosen Who should operate on patients with ovarian cancer? An evidence-based review Gynecol Oncol 99 2005 447 461
12. B.A. Goff, B.J. Matthews, and E.H. Larson Predictors of comprehensive surgical treatment in patients with ovarian cancer Cancer 109 2007 2031 2042
13. M.E. Carney, J.M. Lancaster, C. Ford, A. Tsodikov, and C.L. Wiggins A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not? Gynecol Oncol 84 2002 36 42
14. L. McGowan, L.P. Lesher, H.J. Norris, and M. Barnett Misstaging of ovarian cancer Obstet Gynecol 65 1985 568 572
15. R.C. Bast Jr, T.L. Klug, and E. St John A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer N Engl J Med 309 1983 883 887
16. I. Jacobs, and R.C. Bast Jr The CA 125 tumor-associated antigen: a review of the literature Hum Reprod 4 1989 1 12
17. I. Jacobs, D. Oram, J. Fairbanks, J. Turner, C. Frost, and J.G. Grudzinskas A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer Br J Obstet Gynaecol 97 1990 922 929
18. J. Bailey, A. Tailor, and R. Naik Risk of malignancy index for referral of ovarian cancer cases to a tertiary center: does it identify the correct cases? Int J Gynecol Cancer 16 Suppl 2006 30 34
19. A.P.Pratapkumar Manjunath, K. Sujatha, and R. Vani Comparison of three risk of malignancy indices in evaluation of pelvic masses Gynecol Oncol 81 2001 225 229
20. R.G. Moore, D.S. McMeekin, and A.K. Brown A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass Gynecol Oncol 112 2009 40 46
21. R.G. Moore, A.K. Brown, and M.C. Miller The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass Gynecol Oncol 108 2007 402 408